Aspergilose e COVID-19 em unidade de terapia intensiva brasileira: uma série de casos
DOI:
https://doi.org/10.48017/dj.v8i2.2588Palavras-chave:
COVID-19, SARS-CoV-2, Aspergilose,, Cuidados Críticos, Micoses, CoronavirusResumo
A Aspergilose Pulmonar Associada à COVID-19 (APAC) é uma das principais complicações de pacientes com COVID-19 gravemente doentes. Dessa forma, esse estudo objetivou relatar casos de APAC em pacientes internados em unidade de terapia intensiva de um hospital terciário. Método: Estudo descritivo e retrospectivo que incluiu pacientes com APAC admitidos entre março de 2020 a dezembro de 2021 na unidade de terapia intensiva de um hospital de alta complexidade. Resultados: Do total de oito pacientes com APAC descritos nesse estudo, seis foram classificados como casos possíveis e dois como casos prováveis. Conclusão: Ações preventivas e investigação ativa de aspergilose pulmonar invasiva em pacientes com COVID-19 críticos devem ser realizadas por meio de protocolos de rastreamento e diagnóstico adequados, considerando o alto risco de coinfecção desses pacientes.
Métricas
Referências
Arastehfar, A., Carvalho, A., van de Veerdonk, F. L., Jenks, J. D., Koehler, P., Krause, R., Cornely, O. A., S. Perlin, D., Lass-Flörl, C., & Hoenigl, M. (2020). COVID-19 Associated Pulmonary Aspergillosis (CAPA)—From Immunology to Treatment. Journal of Fungi, 6(2), Art. 2. https://doi.org/10.3390/jof6020091
Bartoletti, M. Epidemiology of Invasive Pulmonary Aspergillosis Among Intubated Patients With COVID-19: A Prospective Study | Clinical Infectious Diseases | Oxford Academic. 2020. https://academic-oup-com.ez34.periodicos.capes.gov.br/cid/article/73/11/e3606/5876990
Borman, A. M., Fountain, H., Guy, R., Casale, E., Genver, S., Elgohari, S., Brown, C., Hopkins, S., Chalker, V., & Johnson, E. (2022). Increased mortality in COVID-19 patients with fungal co- and secondary infections admitted to intensive care or high dependency units in NHS hospitals in England. The Journal of Infection, 84(4), 579–613. https://doi.org/10.1016/j.jinf.2021.12.047
Bounhiol, A., Pasquier, G., Novara, A., Bougnoux, M.-E., & Dannaouiae, E. (2022). Aspergillus detection in airways of ICU COVID-19 patients: To treat or not to treat? Journal of Medical Mycology, 32(3), 101290. https://doi.org/10.1016/j.mycmed.2022.101290
Caggiano, G., Apollonio, F., Consiglio, M., Gasparre, V., Trerotoli, P., Diella, G., Lopuzzo, M., Triggiano, F., Stolfa, S., Mosca, A., & Montagna, M. T. (2022). Tendency in Pulmonary Aspergillosis Investigation during the COVID-19 Era: What Is Changing? International Journal of Environmental Research and Public Health, 19(12), Art. 12. https://doi.org/10.3390/ijerph19127079
Calderón-Parra, J., Mills-Sanchez, P., Moreno-Torres, V., Tejado-Bravo, S., Romero-Sánchez, I., Balandin-Moreno, B., Calvo-Salvador, M., Portero-Azorín, F., García-Masedo, S., Muñez-Rubio, E., Ramos-Martinez, A., Fernández-Cruz, A., & the, H. I. S. G. (2022). COVID-19-associated pulmonary aspergillosis (CAPA): Risk factors and development of a predictive score for critically ill COVID-19 patients. Mycoses, 65(5), 541–550. https://doi.org/10.1111/myc.13434
Castagnoli, R., Votto, M., Licari, A., Brambilla, I., Bruno, R., Perlini, S., Rovida, F., Baldanti, F., & Marseglia, G. L. (2020). Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review. JAMA Pediatrics, 174(9), 882–889. https://doi.org/10.1001/jamapediatrics.2020.1467
Chong, W. H., Saha, B. K., & Neu, K. P. (2022). Comparing the clinical characteristics and outcomes of COVID-19-associate pulmonary aspergillosis (CAPA): A systematic review and meta-analysis. Infection, 50(1), 43–56. https://doi.org/10.1007/s15010-021-01701-x
de Almeida Jr, J. N., Doi, A. M., Watanabe, M. J. L., Maluf, M. M., Calderon, C. L., Silva Jr, M., Pasternak, J., Koga, P. C. M., Santiago, K. A. S., Aranha, L. F. C., Szarf, G., da Silva Teles, G. B., Filippi, R. Z., Paes, V. R., Baeta, M., Hamerschlak, N., Mangueira, C. L. P., & Martino, M. D. V. (2022). COVID-19-associated aspergillosis in a Brazilian referral centre: Diagnosis, risk factors and outcomes. Mycoses, 65(4), 449–457. https://doi.org/10.1111/myc.13433
Egger, M., Bussini, L., Hoenigl, M., & Bartoletti, M. (2022). Prevalence of COVID-19-Associated Pulmonary Aspergillosis: Critical Review and Conclusions. Journal of Fungi, 8(4), Art. 4. https://doi.org/10.3390/jof8040390
Eiden, C., Peyrière, H., Cociglio, M., Djezzar, S., Hansel, S., Blayac, J.-P., & Hillaire-Buys, D. (2007). Adverse Effects of Voriconazole: Analysis of the French Pharmacovigilance Database. Annals of Pharmacotherapy, 41(5), 755–763. https://doi.org/10.1345/aph.1H671
Er, B., Er, A. G., Gülmez, D., Şahin, T. K., Halaçlı, B., Durhan, G., Ersoy, E. O., Alp, A., Metan, G., Saribas, Z., Arikan-Akdagli, S., Hazırolan, G., Akıncı, S. B., Arıyürek, M., Topeli, A., & Uzun, Ö. (2022). A screening study for COVID-19-associated pulmonary aspergillosis in critically ill patients during the third wave of the pandemic. Mycoses, 65(7), 724–732. https://doi.org/10.1111/myc.13466
Floros, L., Kuessner, D., Posthumus, J., Bagshaw, E., Sjö, J., & lin. (2019). Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden. BMC Infectious Diseases, 19(1), NA-NA. https://doi.org/10.1186/s12879-019-3683-2
Gangneux, J.-P., & Dannaoui, A. (2022). Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: The French multicentre MYCOVID study. The Lancet Respiratory Medicine, 10(2), 180–190. https://doi.org/10.1016/S2213-2600(21)00442-2
Ghazanfari, M., Yazdani Charati, J., Davoodi, L., Arastehfar, A., Moazeni, M., Abastabar, M., Haghani, I., Mayahi, S., Hoenigl, M., Pan, W., & Hedayati, M. T. (2022). Comparative analysis of galactomannan lateral flow assay, galactomannan enzyme immunoassay and BAL culture for diagnosis of COVID-19-associated pulmonary aspergillosis. Mycoses, 65(10), 960–968. https://doi.org/10.1111/myc.13518
Greiner, R.-A., Meier, Y., Papadopoulos, G., O’Sullivan, A. K., & Imhof, A. (2010). Cost-Effectiveness of Posaconazole Compared with Standard Azole Therapy for Prevention of Invasive Fungal Infections in Patients at High Risk in Switzerland. Oncology, 78(3–4), 172–180. https://doi.org/10.1159/000313696
Harrington, R., Lee, E., Yang, H., Wei, J., Messali, A., Azie, N., Wu, E. Q., & Spalding, J. (2017). Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis. Advances in Therapy, 34(1), 207–220. https://doi.org/10.1007/s12325-016-0443-1
Hashim, Z., Nath, A., Khan, A., Neyaz, Z., Marak, R. S. K., Areekkara, P., Tiwari, A., Srivastava, S., Agarwal, V., Saxena, S., Tripathy, N., Azim, A., Gupta, M., Mishra, D. P., Mishra, P., Singh, R. K., Gupta, D., Gupta, A., Sanjeev, O. P., … Tripathy, N. K. (2022). New insights into development and mortality of COVID-19-associated pulmonary aspergillosis in a homogenous cohort of 1161 intensive care patients. Mycoses, 65(11), 1010–1023. https://doi.org/10.1111/myc.13485
Koehler, P., Cornely, O. A., Böttiger, B. W., Dusse, F., Eichenauer, D. A., Fuchs, F., Hallek, M., Jung, N., Klein, F., Persigehl, T., Rybniker, J., Kochanek, M., Böll, B., & Shimabukuro-Vornhagen, A. (2020). COVID-19 associated pulmonary aspergillosis. Mycoses, 63(6), 528–534. https://doi.org/10.1111/myc.13096
Koelher, P. K. (2021). Defining and managing COVID-19-associated pulmonary aspergillosis: The 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. The Lancet Infectious Diseases, 21(6), e149–e162. https://doi.org/10.1016/S1473-3099(20)30847-1
Lee, R., Cho, S.-Y., Lee, D.-G., Ahn, H., Choi, H., Choi, S.-M., Choi, J.-K., Choi, J.-H., Kim, S. Y., Kim, Y. J., & Lee, H.-J. (2022). Risk factors and clinical impact of COVID-19-associated pulmonary aspergillosis: Multicenter retrospective cohort study. The Korean Journal of Internal Medicine, 37(4), 851–863. https://doi.org/10.3904/kjim.2022.069
Lim, Jin Lee, Khor, Inn Shih, Moh, Cheng Keat, Chan, Yi Min, Lam, Yoke Fong, & Lachmanan, Kumaresh Raj. (2022). Two cases of COVID-19-associated pulmonary aspergillosis (CAPA). https://doi.org/10.1002/rcr2.940
Machado, M., Valerio, M., Álvarez-Uría, A., Olmedo, M., Veintimilla, C., Padilla, B., De la Villa, S., Guinea, J., Escribano, P., Ruiz-Serrano, M. J., Reigadas, E., Alonso, R., Guerrero, J. E., Hortal, J., Bouza, E., Muñoz, P., & the, C.-19 S. G. (2021). Invasive pulmonary aspergillosis in the COVID-19 era: An expected new entity. Mycoses, 64(2), 132–143. https://doi.org/10.1111/myc.13213
Maertens, J. A., Rahav, G., Lee, D.-G., Ponce-de-León, A., Ramírez Sánchez, I. C., Klimko, N., Sonet, A., Haider, S., Diego Vélez, J., Raad, I., Koh, L.-P., Karthaus, M., Zhou, J., Ben-Ami, R., Motyl, M. R., Han, S., Grandhi, A., & Waskin, H. (2021). Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: A phase 3, randomised, controlled, non-inferiority trial. The Lancet, 397(10273), 499–509. https://doi.org/10.1016/S0140-6736(21)00219-1
Marta, G.-C., Lorena, F.-E., Laura, M.-V., Angela, L.-M., Blanca, L.-G., Rodrigo, A.-A., Marta, S.-G., Santiago, M.-G., Liliana, P.-M., Maria Luisa, S.-N., & de la Rasilla Teresa, P.-G. (2022). COVID-19-Associated Pulmonary Aspergillosis in a Tertiary Hospital. Journal of Fungi, 8(2), Art. 2. https://doi.org/10.3390/jof8020097
Mitaka, H., Perlman, D. C., Javaid, W., & Salomon, N. (2020). Putative invasive pulmonary aspergillosis in critically ill patients with COVID-19: An observational study from New York City. Mycoses, 63(12), 1368–1372. https://doi.org/10.1111/myc.13185
Moreno, R. P., Metnitz, P. G. H., Almeida, E., Jordan, B., Bauer, P., Campos, R. A., Iapichino, G., Edbrooke, D., Capuzzo, M., Le Gall, J.-R., & on behalf of the SAPS 3 Investigators. (2005). SAPS 3—From evaluation of the patient to evaluation of the intensive care unit. Part 2: Development of a prognostic model for hospital mortality at ICU admission. Intensive Care Medicine, 31(10), 1345–1355. https://doi.org/10.1007/s00134-005-2763-5
Musuuza, J. S., Watson, L., Parmasad, V., Putman-Buehler, N., Christensen, L., & Safdar, N. (2021). Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis. PLOS ONE, 16(5), e0251170. https://doi.org/10.1371/journal.pone.0251170
Nasir, N., Farooqi, J., Mahmood, S. F., & Jabeen, K. (2020). COVID‐19‐associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID‐19 pneumonia: An observational study from Pakistan—Nasir—2020—Mycoses—Wiley Online Library.
https://onlinelibrary-wiley.ez34.periodicos.capes.gov.br/doi/full/10.1111/myc.13135
Oliveira, S. Dos C., Santos, C. B. Dos, Lopes, E. K. S., Gomes, K. B., Costa, A. C. B., & Silva, l. J. Da. (2022). Ocorrência de COVID-19 nos países com mais casos no mundo (2019-2021) | Diversitas Journal. 7(3), 1306–1316.
Patterson, T. F., & Donnelly, J. P. (2019). New Concepts in Diagnostics for Invasive Mycoses: Non-Culture-Based Methodologies. Journal of Fungi, 5(1), Art. 1. https://doi.org/10.3390/jof5010009
Patterson, T. F., George R. Thompson, I. I. I., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., Segal, B. H., Steinbach, W. J., Stevens, D. A., Walsh, T. J., Wingard, J. R., Young, J.-A. H., & Bennett, J. E. (2016). Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 63(4), e1. https://doi.org/10.1093/cid/ciw326
Permpalung, N., Maertens, J., & Marr, K. A. (2021). Diagnostic dilemma in COVID-19-associated pulmonary aspergillosis. The Lancet Infectious Diseases, 21(6), 766–767. https://doi.org/10.1016/S1473-3099(21)00060-8
Singh, S., Verma, N., Kanaujia, R., Chakrabarti, A., & Rudramurthy, S. M. (2021). Mortality in critically ill patients with coronavirus disease 2019-associated pulmonary aspergillosis: A systematic review and meta-analysis. Mycoses, 64(9), 1015–1027. https://doi.org/10.1111/myc.13328
Tio, S. Y., Williams, E., Worth, L. J., Deane, A. M., Bond, K., Slavin, M. A., & Sasadeusz, J. (2021). Invasive pulmonary aspergillosis in critically ill patients with COVID-19 in Australia: Implications for screening and treatment. Internal Medicine Journal, 51(12), 2129–2132. https://doi.org/10.1111/imj.15602
Ullman, A., Aguado, J., Arikan-Akdagli, S., Denning, D. W., Groll, A., Lagrou, K., Lass-Flörl, C., Lewis, R., & Munoz, P. (2018). Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clinical Microbiology and Infection, 24, e1–e38. https://doi.org/10.1016/j.cmi.2018.01.002
WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination. (2022). https://:covid19.who.int
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., Niu, P., Zhan, F., Ma, X., Wang, D., Xu, W., Wu, G., Gao, G. F., & Tan, W. (2020). A Novel Coronavirus from Patients with Pneumonia in China, 2019. New England Journal of Medicine, 382(8), 727–733. https://doi.org/10.1056/NEJMoa2001017
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2023 Adriana Sousa-Neto, Clesnan Mendes-Rodrigues, Reginaldo dos Santos Pedroso dos Santos Pedroso, Denise Von Dolinger de Brito Röder Röder
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
O periodico Diversitas Journal expressa que os artigos são de unica responsabilidade dos Autores, conhecedores da legislação Brasileira e internacional. Os artigos são revisados pelos pares e devem ter o cuidado de avisar da possível incidencia de plagiarismo. Contudo o plagio é uma ação incontestavel dos autores. A Diversitas Journal não publicará artigos com indicios de Plagiarismos. Artigos com plagios serão tratados em conformidade com os procedimentos de plagiarismo COPE.
A violação dos direitos autorais constitui crime, previsto no artigo 184, do Código Penal Brasileiro:
“Art. 184 Violar direitos de autor e os que lhe são conexos: Pena – detenção, de 3 (três) meses a 1 (um) ano, ou multa. § 1o Se a violação consistir em reprodução total ou parcial, com intuito de lucro direto ou indireto, por qualquer meio ou processo, de obra intelectual, interpretação, execução ou fonograma, sem autorização expressa do autor, do artista intérprete ou executante, do produtor, conforme o caso, ou de quem os represente: Pena – reclusão, de 2 (dois) a 4 (quatro) anos, e multa.”
.png){kind=logo}
